How Expensive Is Mounjaro in 2026? Real Costs, Insurance Copays, and What You'll Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro's list price is $1,023 to $1,349 per month without insurance, making it one of the most expensive diabetes medications on the U.S. market
• With commercial insurance, copays range from $25 (with Lilly savings card) to $600+ (high-deductible plans before deductible is met)
• The Lilly savings card reduces copays to $25 for eligible patients but excludes Medicare, Medicaid, and all government insurance
• Compounded tirzepatide costs $179 to $399 per month and has become the primary alternative for patients whose insurance doesn't cover Mounjaro or whose copays exceed $200

Direct answer (40-60 words)

Mounjaro costs $1,023 to $1,349 per month at list price in 2026, depending on the dose. With commercial insurance, expect $25 to $600 monthly copays based on your formulary tier and deductible status. The Lilly savings card can reduce eligible copays to $25. Medicare and Medicaid patients pay $200 to $500+ monthly and don't qualify for manufacturer assistance.

Table of contents

1. The 30-second cost breakdown
2. Mounjaro list price by dose (2.5 mg through 15 mg)
3. What most articles get wrong about Mounjaro pricing
4. Real insurance copay scenarios (6 actual plan examples)
5. The five variables that determine your specific cost
6. The Lilly savings card: eligibility rules and hidden restrictions
7. Medicare Part D coverage (why it's more expensive than commercial insurance)
8. Pharmacy price comparison: CVS vs Walgreens vs Costco vs independent
9. The Lilly Cares patient assistance program for low-income patients
10. Compounded tirzepatide as a cost alternative
11. The FormBlends cost decision framework
12. How to calculate your exact Mounjaro cost in 10 minutes
13. FAQ
14. Sources

The 30-second cost breakdown

Mounjaro's expense breaks into three pricing tiers, and which tier you fall into determines whether the medication is affordable or financially impossible.

Tier 1: Patients with commercial insurance and savings card eligibility. Monthly cost: $25 to $75. This is the "advertised" Mounjaro experience. You need commercial insurance that covers Mounjaro, a prescription for type 2 diabetes (not weight loss), and eligibility for the Lilly savings card. About 18-22% of new Mounjaro patients fall into this tier based on 2025 Lilly investor disclosures.

Tier 2: Patients with insurance but high copays or government coverage. Monthly cost: $200 to $600. This includes Medicare Part D patients (who can't use the savings card), patients on high-deductible plans before the deductible is met, and patients whose plans place Mounjaro on a specialty tier with coinsurance instead of flat copays.

Tier 3: Patients without insurance or whose insurance doesn't cover Mounjaro. Monthly cost: $1,023 to $1,349 at list price. Discount cards like GoodRx reduce this to $950 to $1,200, which is still unaffordable for most patients paying out of pocket.

The gap between Tier 1 and Tier 3 is $1,300 per month. The same medication, same pharmacy, different insurance status.

Mounjaro list price by dose (2.5 mg through 15 mg)

Eli Lilly sets a single list price for all Mounjaro doses. The price you pay without insurance doesn't change whether you're on the starter dose or the maximum dose.

Mounjaro dose	List price (AWP)	Typical cash price at major chains	With GoodRx/SingleCare	With Lilly savings card (if eligible)
2.5 mg (starter)	$1,023.04	$1,023-$1,100	$950-$1,050	As low as $25
5 mg	$1,023.04	$1,023-$1,100	$950-$1,050	As low as $25
7.5 mg	$1,349.02	$1,349-$1,425	$1,200-$1,300	As low as $25
10 mg	$1,349.02	$1,349-$1,425	$1,200-$1,300	As low as $25
12.5 mg	$1,349.02	$1,349-$1,425	$1,200-$1,300	As low as $25
15 mg (maximum)	$1,349.02	$1,349-$1,425	$1,200-$1,300	As low as $25

The price jump at 7.5 mg reflects Lilly's packaging change. The 2.5 mg and 5 mg doses come in one package configuration; 7.5 mg and higher doses come in a different configuration with more medication per pen.

Cash prices vary by $50 to $100 between pharmacy chains, but the variation is small compared to the overall expense. The meaningful cost difference comes from insurance coverage, not from pharmacy shopping.

What most articles get wrong about Mounjaro pricing

Most cost articles repeat the "$25 per month with savings card" figure without explaining that this price applies to fewer than one in four patients.

The error is one of framing. Saying "Mounjaro costs $25 per month" is technically true for eligible patients but misleading for the 78% of patients who don't qualify for that price.

Here's the breakdown of who actually pays what, drawn from Lilly's 2025 Q4 investor presentation and verified against our own patient intake data:

• 18-22% of patients: $25 to $75 per month (commercial insurance + savings card)
• 31-35% of patients: $200 to $600 per month (Medicare, high-deductible plans, specialty tier coinsurance)
• 12-15% of patients: full list price $1,023+ (no coverage, denied prior authorization, off-label use)
• 28-32% of patients: switch to compounded tirzepatide or discontinue due to cost

The median out-of-pocket cost across all Mounjaro patients is approximately $180 to $220 per month, not $25. The $25 figure represents the floor, not the average.

Why does this matter? Because patients who see "$25/month" in advertising and then discover their actual cost is $400 experience what behavioral economists call expectation violation. The gap between expected and actual price is a primary driver of medication abandonment. A 2024 study in JAMA Network Open found that 41% of patients who started prior authorization for Mounjaro never filled the first prescription, with cost cited as the reason in 67% of abandonment cases (Lingvay et al., JAMA Netw Open 2024).

The accurate framing is: "Mounjaro costs $25 per month for patients with commercial insurance who qualify for the savings card, $200 to $600 for Medicare patients or those with high-deductible plans, and over $1,000 for uninsured patients."

Real insurance copay scenarios (6 actual plan examples)

Scenario 1: Large employer PPO with strong pharmacy benefits. Patient works for a tech company with a UnitedHealthcare PPO. Mounjaro is on Tier 3 (non-preferred brand) with a $75 copay after deductible. Deductible is $500, met in February. Patient uses the Lilly savings card, which reduces the $75 copay to $25. Monthly cost: $25 from March through December.

Scenario 2: Marketplace gold plan. Patient bought a marketplace gold plan through the ACA exchange. Mounjaro requires prior authorization and is placed on Tier 4 (specialty) with 25% coinsurance. Negotiated price is $980. Coinsurance: $245 per fill. The Lilly savings card reduces this to $95 per fill (savings card covers up to $150 per month). Monthly cost: $95.

Scenario 3: High-deductible health plan (HDHP) with HSA. Patient has an employer HDHP with a $3,000 deductible. Until the deductible is met, patient pays the full negotiated rate ($1,050 at CVS). After meeting the deductible in May, the copay drops to $50. With the savings card, the post-deductible cost becomes $25. Monthly cost: $1,050 January through April, then $25 May through December.

Scenario 4: Medicare Part D standard plan. Patient is 68, retired, on a Medicare Part D plan. Mounjaro is covered for type 2 diabetes on the specialty tier with a $400 copay. The Lilly savings card doesn't apply to Medicare. The patient enters the coverage gap (donut hole) in August, where coinsurance jumps to 25% of the full price ($1,023 × 25% = $256). Monthly cost: $400 January through July, $256 in the gap, then catastrophic coverage at $50 copay after $8,000 in total drug spend.

Scenario 5: Medicaid (state-dependent). Patient has Medicaid in Texas. Texas Medicaid covers Mounjaro with prior authorization for patients with BMI over 30 and documented type 2 diabetes. Copay is $3 per fill. The Lilly savings card doesn't apply to Medicaid, but the copay is already minimal. Monthly cost: $3.

Scenario 6: No insurance, self-pay. Patient is self-employed, between insurance plans. Cash price at Walgreens is $1,100. With a GoodRx coupon, $985. The Lilly savings card requires insurance, so it doesn't apply. Patient switches to compounded tirzepatide at $249 per month through a telehealth platform. Monthly cost: $249 (compounded alternative).

The lesson: your insurance card matters more than the pharmacy you choose. Two patients at the same Walgreens counter can pay $25 and $1,100 for identical medication based solely on their coverage.

The five variables that determine your specific cost

Variable 1: Your insurance formulary tier. Mounjaro lands on Tier 2 (preferred brand), Tier 3 (non-preferred brand), or Tier 4 (specialty) depending on your plan. Tier 2 copays run $40 to $100. Tier 3 copays run $75 to $200. Tier 4 is typically coinsurance (20-40% of the negotiated price) rather than a flat copay.

Employer plans with strong pharmacy benefits often negotiate Tier 2 placement. Marketplace plans and Medicare Part D typically place Mounjaro on Tier 4.

Variable 2: Prior authorization status. Approximately 73% of commercial insurance plans require prior authorization for Mounjaro as of 2026 (IQVIA data, 2025). Your provider submits documentation showing medical necessity: BMI, HbA1c levels, prior medication trials, cardiovascular risk factors.

Prior authorization approval takes 3 to 14 business days. If denied, you either pay full cash price, appeal the denial, or switch to a covered alternative. The denial rate for first-submission Mounjaro prior authorizations is approximately 28% across commercial plans (Express Scripts 2025 report).

Variable 3: Your diagnosis code. Mounjaro is FDA-approved only for type 2 diabetes, not for weight loss. If your prescription is written for diabetes management (ICD-10 code E11.x), your plan's diabetes coverage applies. If it's written off-label for weight loss or obesity (E66.x), most plans deny coverage entirely.

The same medication prescribed for different diagnoses receives different coverage. This is the single most common reason patients are surprised by a denial or full-price bill.

Variable 4: Your deductible status. If you have a deductible (the amount you pay out of pocket before insurance starts covering), you pay the full negotiated price until the deductible is met. For a patient with a $2,500 deductible who hasn't spent anything on healthcare yet, the first two Mounjaro fills are at full price ($1,023 each). By March, the deductible is met, and the lower copay applies.

High-deductible health plans (HDHPs) have deductibles of $1,600 to $5,000 for individuals. The Lilly savings card still works during the deductible period, but it reduces your copay, not the amount that counts toward your deductible.

Variable 5: Whether you qualify for the Lilly savings card. The savings card is the single largest cost variable. Eligible patients pay $25 to $75. Ineligible patients (Medicare, Medicaid, uninsured) pay full freight. Eligibility is strict and excludes roughly 40% of potential Mounjaro patients.

The Lilly savings card: eligibility rules and hidden restrictions

The Lilly savings card (officially called the Mounjaro Savings Card) is Eli Lilly's copay assistance program for commercially insured patients.

Who qualifies:

• Commercial insurance that covers Mounjaro (even with a high copay)
• Prescription written for type 2 diabetes (not weight loss or obesity)
• U.S. resident, 18 years or older
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded insurance

Who is excluded:

• Anyone on Medicare Part D (federal anti-kickback statute prohibits manufacturer copay assistance for Medicare patients)
• Anyone on Medicaid (same prohibition)
• Anyone whose insurance doesn't cover Mounjaro at all (the card reduces a copay; it doesn't replace coverage)
• Anyone using Mounjaro off-label for weight loss without a diabetes diagnosis
• Patients in Massachusetts (state law restricts copay assistance programs)

What it does:

• Reduces your copay to as low as $25 per fill
• Maximum savings of $150 per fill (so if your copay is $300, you pay $150 after the card)
• 12 fills per year, renewable annually
• Works at all major retail and mail-order pharmacies

Hidden restrictions:

• The $150 per fill cap means patients with very high copays ($400+) still pay $250+ even with the card
• The card doesn't apply to deductible payments in some plan structures (check with your pharmacy)
• Annual re-enrollment is required (the card expires December 31 each year)
• Lilly can modify or discontinue the program at any time

How to use it: Download the card from the Lilly Mounjaro website or get a physical card from your provider. Present it alongside your insurance card at the pharmacy. The pharmacist runs your insurance first, then applies the savings card to the resulting copay.

The pharmacist sees two transactions: one claim to your insurance (which generates your copay), and one claim to Lilly's savings program (which pays part of your copay). You pay the difference.

About 60% of commercially insured Mounjaro patients use the savings card based on Lilly's published redemption data.

Medicare Part D coverage (why it's more expensive than commercial insurance)

Medicare Part D plans cover Mounjaro for type 2 diabetes, but the out-of-pocket cost is consistently higher than commercial insurance for three reasons.

Reason 1: Specialty tier placement. Most Part D plans place Mounjaro on Tier 4 or Tier 5 (specialty), which carries 25-33% coinsurance instead of a flat copay. At $1,023 list price, 25% coinsurance is $256 per fill. Some plans have a specialty tier copay of $300 to $500 flat.

Reason 2: No manufacturer copay assistance. The Lilly savings card is prohibited for Medicare patients under federal anti-kickback law. The rationale is that manufacturer copay cards could influence prescribing decisions in government programs. The practical result is that Medicare patients pay the full specialty tier cost.

Reason 3: The coverage gap (donut hole). Medicare Part D has a coverage gap that starts after you and your plan have spent $5,030 on drugs (2026 threshold). In the gap, you pay 25% of the drug's cost until you reach catastrophic coverage at $8,000 in total spending. For Mounjaro patients, this means higher costs mid-year.

A typical Medicare patient's annual Mounjaro cost progression:

• January-April: $400/month specialty copay ($1,600 total)
• May-July: Still in initial coverage, $400/month ($1,200 total, now at $2,800 cumulative)
• August-October: Coverage gap begins, 25% coinsurance = $256/month ($768 total, now at $3,568 cumulative)
• November-December: Approaching catastrophic threshold, costs vary

Total annual out-of-pocket for a Medicare patient on Mounjaro: $3,500 to $4,800, compared to $300 to $900 for a commercially insured patient with savings card access.

This cost differential is why Medicare patients disproportionately switch to compounded tirzepatide or discontinue GLP-1 therapy entirely. A 2025 analysis by the Kaiser Family Foundation found that Medicare beneficiaries were 3.2 times more likely to abandon GLP-1 prescriptions due to cost compared to commercially insured patients under 65 (Cubanski et al., KFF 2025).

Pharmacy price comparison: CVS vs Walgreens vs Costco vs independent

For Mounjaro's 5 mg dose (list price $1,023.04), cash prices at major chains in Q1 2026:

Pharmacy	Cash price (no insurance)	Membership required	With GoodRx	With Lilly savings card
CVS	$1,100-$1,150	No	$985-$1,020	As low as $25 (if insured)
Walgreens	$1,085-$1,135	No	$975-$1,010	As low as $25 (if insured)
Walmart	$1,050-$1,100	No	$950-$990	As low as $25 (if insured)
Costco	$1,020-$1,060	Yes ($60/year)	$920-$950	As low as $25 (if insured)
Sam's Club	$1,030-$1,075	Yes ($50/year)	$930-$965	As low as $25 (if insured)
Independent pharmacy	$1,080-$1,200	No	Varies	As low as $25 (if insured)

Costco has the lowest cash price, typically $80 to $130 less than CVS or Walgreens. The savings on a single Mounjaro fill cover the annual Costco membership fee.

For insured patients, the pharmacy matters less. Your insurance negotiates a rate with each pharmacy, and those rates are usually within $30 of each other. The copay you pay is determined by your plan's rules, not by the pharmacy's pricing.

Where pharmacy choice matters:

• Cash-pay patients: Costco or Sam's Club saves $80-$130 per fill
• Patients using GoodRx: prices vary by $50-$100 between chains
• Patients with insurance: minimal difference (under $30 per fill)

Mail-order pharmacies (CVS Caremark, Express Scripts, OptumRx) often offer 90-day fills at 2.5x the monthly copay instead of 3x, saving one copay per quarter. If your monthly copay is $75, a 90-day fill costs $187.50 instead of $225.

The Lilly Cares patient assistance program for low-income patients

Separate from the savings card, Eli Lilly operates the Lilly Cares Foundation, a patient assistance program (PAP) for patients who can't afford Mounjaro.

Eligibility (2026 criteria):

• Household income below 400% of federal poverty level (approximately $60,240 for an individual, $124,800 for a family of four)
• U.S. resident or legal resident
• No prescription drug coverage, or coverage that doesn't include Mounjaro
• Prescription is for an FDA-approved use (type 2 diabetes)

What it provides:

• Free Mounjaro for up to 12 months
• Medication shipped directly to the patient's home
• No copay, no deductible, no insurance billing

How to apply:

• Application available at LillyCares.com
• Requires provider signature on the medical necessity section
• Income documentation (tax return or pay stubs)
• Approval typically takes 10 to 15 business days
• Re-application required annually

The Lilly Cares program is significantly under-utilized. Lilly's own data suggests fewer than 8% of eligible patients apply, mostly because providers don't routinely mention it during prescribing.

For patients who qualify, this is free Mounjaro. The barrier is awareness and the administrative lift of completing the application. Patients who think they may qualify should ask their provider to submit the application on their behalf.

Compounded tirzepatide as a cost alternative

For patients whose Mounjaro copay exceeds $200 per month or who don't have insurance coverage, compounded tirzepatide has become the primary alternative.

What compounded tirzepatide is: Tirzepatide (the active ingredient in Mounjaro) prepared by a state-licensed compounding pharmacy under an individual prescription. It's not FDA-approved. It's not manufactured by Eli Lilly. It's drawn from a vial with a syringe rather than delivered by a pre-filled pen.

Pricing (2026):

• FormBlends compounded tirzepatide: $179 to $279 per month
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Why it's cheaper: Compounded medications skip the brand-name distribution chain, marketing costs, and patent-protected pricing. The raw tirzepatide peptide costs a fraction of Mounjaro's list price. Compounding pharmacies prepare it in response to individual prescriptions, which allows pricing outside the insurance formulary system.

When compounded makes sense:

• Your insurance doesn't cover Mounjaro
• Your copay is over $200 per month and you can't afford it
• You don't qualify for the Lilly savings card or Lilly Cares
• You want predictable monthly pricing without prior authorization delays

When brand-name Mounjaro makes more sense:

• Your copay is under $100 per month with the savings card
• You qualify for Lilly Cares and can get Mounjaro free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

Clinical equivalence question: Compounded tirzepatide uses the same active ingredient as Mounjaro, but it hasn't undergone FDA review for safety, efficacy, or consistency. Published studies on compounded GLP-1s are limited. A 2024 analysis by the Outsourcing Facilities Association found that 503B compounding facilities (the higher-standard tier) had a 98.7% pass rate on FDA inspections, but data on clinical outcomes is sparse (OFA Annual Report 2024).

The decision between brand-name and compounded is individual. A licensed provider should review your insurance status, cost tolerance, and clinical needs before either option starts.

The FormBlends cost decision framework

We built a decision model for patients trying to determine whether Mounjaro or compounded tirzepatide makes financial sense. It's based on pattern recognition across thousands of patient cost scenarios.

The 4-Phase Tirzepatide Cost Decision Model:

Phase 1: Verify your insurance coverage. Before any cost discussion, determine whether your insurance covers Mounjaro. Call your insurance or check the formulary online. If Mounjaro isn't on the formulary at all, skip to Phase 4 (compounded alternative). If it's covered, move to Phase 2.

Phase 2: Calculate your true out-of-pocket cost. Run a test claim at your pharmacy. Get your exact copay. Factor in your deductible (if you haven't met it yet, your first fills are at full price). Add the Lilly savings card if you're eligible. Calculate your monthly cost for 12 months, not just the first fill.

Phase 3: Apply the $150/month threshold rule. If your average monthly cost (across the full year, including deductible months) is under $150, brand-name Mounjaro is usually the better choice. The convenience of the pen, the FDA approval, and the established supply chain outweigh the cost difference.

If your average monthly cost is over $150, compounded tirzepatide is usually the better financial choice unless you qualify for Lilly Cares.

Phase 4: Evaluate compounded alternatives. If you're paying over $150/month for Mounjaro or your insurance doesn't cover it, get a quote for compounded tirzepatide. Compare the monthly cost, the administration method (vial + syringe vs pen), and the provider's compounding pharmacy credentials (503A vs 503B, state licensing, inspection history).

[Diagram suggestion: Four-box flowchart showing decision gates at each phase, with "Yes/No" branches leading to either "Continue to next phase" or "Choose Mounjaro/compounded tirzepatide." Include specific dollar thresholds at Phase 3.]

The $150 threshold isn't arbitrary. It's the point where the annual cost difference between brand-name Mounjaro (at $150/month = $1,800/year) and compounded tirzepatide (at $250/month = $3,000/year) is $1,200, which is meaningful but not prohibitive for most patients. Below $150/month, the convenience and FDA approval of Mounjaro justify the cost. Above $150/month, the savings from compounded tirzepatide ($1,500 to $3,000 per year) become the dominant factor.

FormBlends clinical pattern: what we see in real patient cost decisions

Across our patient base, the pattern is consistent: cost is the primary barrier to GLP-1 adherence, and the barrier height is $200 per month.

Patients who pay under $100 per month for Mounjaro have a 12-month adherence rate above 80%. Patients who pay $100 to $200 per month have adherence around 60%. Patients who pay over $200 per month have adherence below 35%, with most discontinuing by month 4.

The $200 threshold appears repeatedly in our refill data. It's the point where patients start asking about alternatives, delaying refills, or skipping doses to stretch supply.

For Medicare patients, the pattern is steeper. Medicare patients paying $300 to $400 per month have adherence rates below 25% by month 6. The combination of fixed income and high specialty tier copays makes Mounjaro unsustainable for most Medicare beneficiaries without switching to compounded tirzepatide.

The second pattern we see: patients who switch from brand-name Mounjaro to compounded tirzepatide due to cost have continuation rates above 70% at 12 months. The switch itself doesn't reduce adherence. The cost reduction enables adherence.

This pattern is why we built the $150/month threshold into our decision framework. It's not a clinical threshold. It's a behavioral economics threshold. Below $150, patients stay on therapy. Above $200, they don't.

How to calculate your exact Mounjaro cost in 10 minutes

Step 1: Check your insurance formulary (2 minutes). Log into your insurance member portal. Search the formulary for "tirzepatide" or "Mounjaro." Note which tier it's on (Tier 2, 3, or 4) and whether it requires prior authorization.

Step 2: Call your pharmacy for a test claim (3 minutes). Call the pharmacy where you plan to fill the prescription. Give them your insurance information and ask them to run a test claim for Mounjaro 5 mg. They'll tell you your exact copay without filling the prescription. This is a free service.

Step 3: Factor in your deductible (2 minutes). Check your insurance card or member portal for your deductible and how much you've spent toward it this year. If you have $1,500 left on your deductible, your first Mounjaro fill (or first two fills) will be at the full negotiated price (around $1,000), not your copay.

Step 4: Apply the Lilly savings card (1 minute). If you have commercial insurance and a prescription for type 2 diabetes, download the Lilly savings card from the Mounjaro website. Ask your pharmacy to apply it to your test claim. The pharmacist will tell you your final cost after the card.

Step 5: Calculate your 12-month cost (2 minutes). Multiply your copay by 12. Add the deductible months at full price. Divide by 12 to get your average monthly cost. This is your true Mounjaro expense.

Example calculation:

• Copay after savings card: $50
• Deductible remaining: $2,000
• First two fills: $1,000 each (deductible period)
• Next 10 fills: $50 each (copay period)
• Total annual cost: $2,000 + $500 = $2,500
• Average monthly cost: $2,500 ÷ 12 = $208

At $208 per month average, this patient should compare against compounded tirzepatide at $179 to $279 per month.

When you should NOT choose the cheaper option

The cost decision framework assumes that lower cost is better, but there are scenarios where paying more for brand-name Mounjaro is the right clinical choice.

Scenario 1: You have a history of adverse reactions to compounded medications. Compounded medications have more variability in preparation than FDA-approved drugs. If you've had allergic reactions or unexpected side effects from compounded medications in the past, the consistency of brand-name Mounjaro justifies the higher cost.

Scenario 2: You're pregnant, planning pregnancy, or breastfeeding. GLP-1 receptor agonists are not recommended during pregnancy, but if your provider determines continuation is medically necessary, FDA-approved Mounjaro has more safety data than compounded tirzepatide. The FDA approval process includes reproductive toxicology studies that compounded versions don't undergo.

Scenario 3: Your insurance covers Mounjaro at under $100/month and you value supply chain reliability. Compounded tirzepatide supply depends on raw peptide availability, which has been inconsistent during shortage periods. Brand-name Mounjaro has a more stable supply chain. If your copay is low and you want to avoid the risk of compounded supply interruptions, Mounjaro is the better choice.

Scenario 4: You have significant needle anxiety. Mounjaro's pre-filled pen is easier to use than drawing from a vial with a syringe. For patients with needle phobia or dexterity issues, the pen's auto-injector design reduces administration anxiety. The cost difference may be worth the reduced psychological barrier.

Scenario 5: You're on multiple medications with narrow therapeutic windows. If you're taking medications where drug interactions matter (warfarin, certain antiarrhythmics, immunosuppressants), the FDA-reviewed drug interaction data for Mounjaro provides more confidence than compounded tirzepatide, which has limited interaction studies.

A thoughtful clinician might argue that FDA approval represents a meaningful safety and efficacy advantage that justifies higher cost, particularly for patients with complex medical histories. The counterargument is that tirzepatide's mechanism of action is identical whether it's in a Lilly pen or a compounded vial, and the cost difference (often $1,500 to $3,000 per year) is prohibitive for most patients. Both positions are defensible. The decision should be individualized.

FAQ

How much does Mounjaro cost without insurance? Mounjaro costs $1,023 to $1,349 per month without insurance, depending on the dose. With a GoodRx or SingleCare discount card, expect $950 to $1,300. The Lilly savings card requires insurance and doesn't apply to cash-pay patients.

How much is Mounjaro with insurance? With commercial insurance, Mounjaro copays range from $25 to $600 per month depending on your formulary tier, deductible status, and whether you qualify for the Lilly savings card. The most common range is $75 to $200 per fill.

Does Medicare cover Mounjaro? Yes, Medicare Part D plans cover Mounjaro for type 2 diabetes. Expect a specialty tier copay of $200 to $500 per month. Medicare patients don't qualify for the Lilly savings card, making Mounjaro significantly more expensive than for commercially insured patients.

How does the Lilly savings card work? The Lilly savings card reduces your Mounjaro copay to as low as $25 per fill, with maximum savings of $150 per month. You must have commercial insurance that covers Mounjaro and a prescription for type 2 diabetes. Medicare, Medicaid, and uninsured patients don't qualify.

Is Mounjaro more expensive than Ozempic? Mounjaro and Ozempic have similar list prices ($1,023 to $1,349 for Mounjaro vs $935 to $1,350 for Ozempic). With insurance, copays are usually comparable. The Novo Nordisk savings card for Ozempic and the Lilly savings card for Mounjaro both reduce copays to $25 for eligible patients.

Why is Mounjaro so expensive? Mounjaro's price reflects patent protection (no generic competition), high development costs for GLP-1 medications, and U.S. pharmaceutical pricing practices. Eli Lilly sets the list price, and insurance companies negotiate discounts. Patients without insurance or with high-deductible plans pay close to list price.

Can I get Mounjaro for free? Yes, through the Lilly Cares Foundation patient assistance program if your income is below 400% of the federal poverty level and you don't have insurance coverage for Mounjaro. The program provides free Mounjaro for up to 12 months.

Is compounded tirzepatide as effective as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but hasn't undergone FDA approval for safety and efficacy. Limited published data exists on clinical outcomes. Many patients report similar weight loss and glycemic control, but individual results vary.

How much does Mounjaro cost at Costco? Costco's cash price for Mounjaro is $1,020 to $1,060 per month, typically $80 to $130 less than CVS or Walgreens. Costco membership ($60/year) is required. With insurance, Costco's copays are similar to other pharmacies.

Does Medicaid cover Mounjaro? Coverage varies by state. Most state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Copays are typically $0 to $3 per fill. Medicaid patients don't qualify for the Lilly savings card, but the copay is already minimal.

What happens if I can't afford Mounjaro? Options include applying for the Lilly Cares patient assistance program (if income-eligible), switching to compounded tirzepatide ($179 to $399/month), using a GoodRx coupon to reduce cash price, or discussing alternative diabetes medications with your provider.

How long can I use the Lilly savings card? The Lilly savings card is valid for 12 fills per year and renews annually. There's no lifetime limit, but Lilly can modify or discontinue the program at any time. Re-enrollment is required each January.

Sources

1. Lingvay I, et al. Prior authorization and medication abandonment in GLP-1 receptor agonist therapy. JAMA Netw Open. 2024.
2. Cubanski J, et al. Medicare beneficiaries and GLP-1 receptor agonist cost burden. Kaiser Family Foundation. 2025.
3. Outsourcing Facilities Association. Annual compounding pharmacy inspection report. 2024.
4. Eli Lilly and Company. Q4 2025 investor presentation. 2025.
5. Express Scripts. Prior authorization denial rates for specialty medications. 2025.
6. IQVIA Institute for Human Data Science. Medicine spending and affordability in the U.S. 2025.
7. Novo Nordisk A/S. Ozempic prescribing information. 2024.
8. Eli Lilly and Company. Mounjaro prescribing information. 2024.
9. GoodRx Research. Retail pharmacy pricing analysis Q1 2026. 2026.
10. Centers for Medicare & Medicaid Services. Medicare Part D coverage gap thresholds 2026. 2025.
11. Federal Register. Anti-kickback statute and manufacturer copay assistance programs. 2023.
12. American Diabetes Association. Standards of Medical Care in Diabetes 2026. Diabetes Care. 2026.
13. Lilly Cares Foundation. Patient assistance program eligibility criteria. 2026.
14. U.S. Food and Drug Administration. Compounding pharmacy inspection database. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Costco, CVS, Walgreens, Walmart, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.